HUP0401344A2 - Gyógyszerkészítmények opioidokkal való visszaélés megakadályozására, és eljárás előállításukra - Google Patents

Gyógyszerkészítmények opioidokkal való visszaélés megakadályozására, és eljárás előállításukra

Info

Publication number
HUP0401344A2
HUP0401344A2 HU0401344A HUP0401344A HUP0401344A2 HU P0401344 A2 HUP0401344 A2 HU P0401344A2 HU 0401344 A HU0401344 A HU 0401344A HU P0401344 A HUP0401344 A HU P0401344A HU P0401344 A2 HUP0401344 A2 HU P0401344A2
Authority
HU
Hungary
Prior art keywords
dosage form
effective amount
approx
administration
nasal
Prior art date
Application number
HU0401344A
Other languages
English (en)
Inventor
Christopher Breder
Robert Colucci
Benjamin Oshlack
Richard Sackler
Curtis Wright
Original Assignee
Euro-Celtique S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro-Celtique S.A. filed Critical Euro-Celtique S.A.
Publication of HUP0401344A2 publication Critical patent/HUP0401344A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Abstract

A találmány tárgya szabályozott hatóanyag-leadású orális dózisforma,amely opioidokkal való visszaélés elkövetésére alkalmas hatóanyagterápiásan hatékony mennyiségét, egy vagy több gyógyászatilagelfogadható segédanyaggal együtt tartalmazza; a dózisforma egygélesítőszert is magában foglal, hatékony mennyiségben ahhoz, hogy adózisforma összetörésével és kb. 0,5 ml és kb. 10 ml közöttimenynyiségű vizes folyadékkal való összekeverésével előállítottszolubilizált elegyet parenterális vagy nazális adagolásra alkalmatlanmértékben viszkózussá tegye; a dózisforma legalább kb. 12 órán át fejtki terápiás hatást egy humán betegben, orális adagolást követően. Egymásik, találmány szerinti szabályozott hatóanyag-leadású orálisdózisforma egy olyan gélesítőszert foglal magában, amely a dózisformaösszetörésével és kb. 0,5 ml és kb. 10 ml közötti mennyiségű vizesfolyadékkal való összekeverésével, majd melegítésével előállítottszolubilizált elegyet parenterális vagy nazális adagolásra alkalmatlanmértékben viszkózussá teszi. Egy további, találmány szerinti orálisdózisforma olyan gélesítőszer hatékony mennyiségét foglalja magábanviszkózusság létrehozásához, amely a dózisforma manipulálása után azorrjáratokra való adagolás során a hatóanyag nazális felszívódásáhoznem megfelelő. Szintén a találmány tárgyát képezik az olyan orálisdózisformák, amelyek egy visszaélés elkövetésére alkalmas hatóanyagterápiásan hatékony mennyiségét és vagy egy irritálószer hatékonymennyiségét, vagy egy keserű ízt adó szer hatékony mennyiségétfoglalják magukban. A találmány kiterjed a fenti gyógyászatidózisformák előállítási eljárására is. Ó
HU0401344A 2001-08-06 2002-08-06 Gyógyszerkészítmények opioidokkal való visszaélés megakadályozására, és eljárás előállításukra HUP0401344A2 (hu)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31051401P 2001-08-06 2001-08-06
US31053501P 2001-08-06 2001-08-06
US31053401P 2001-08-06 2001-08-06
PCT/US2002/024935 WO2003013476A1 (en) 2001-08-06 2002-08-06 Compositions and methods to prevent abuse of opioids

Publications (1)

Publication Number Publication Date
HUP0401344A2 true HUP0401344A2 (hu) 2004-11-29

Family

ID=27405461

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401344A HUP0401344A2 (hu) 2001-08-06 2002-08-06 Gyógyszerkészítmények opioidokkal való visszaélés megakadályozására, és eljárás előállításukra

Country Status (10)

Country Link
EP (1) EP1414413A1 (hu)
JP (1) JP2005500364A (hu)
KR (1) KR20040025741A (hu)
BR (1) BR0212020A (hu)
CA (1) CA2455420A1 (hu)
DE (1) DE20220917U1 (hu)
HU (1) HUP0401344A2 (hu)
IL (1) IL160217A0 (hu)
MX (1) MXPA04001206A (hu)
WO (1) WO2003013476A1 (hu)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ505193A (en) 1997-12-22 2003-03-28 Euro Celtique S Opioid agonist/antagonist combinations
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
JP4522652B2 (ja) 2001-05-11 2010-08-11 エンドー ファーマシューティカルズ， インコーポレイティド 乱用防止制御放出オピオイド投薬形態
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
US9820982B2 (en) 2001-07-06 2017-11-21 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
US20030068276A1 (en) 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
EP2425823A1 (en) 2002-04-05 2012-03-07 Euro-Celtique S.A. Pharmaceutical preparation containing oxycodone and naloxone
ATE419840T1 (de) 2002-04-09 2009-01-15 Flamel Tech Sa Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
DE10250083A1 (de) * 2002-06-17 2003-12-24 Gruenenthal Gmbh Gegen Missbrauch gesicherte Darreichungsform
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
WO2004026283A1 (en) * 2002-09-20 2004-04-01 Alpharma, Inc. Sequestering subunit and related compositions and metohds
DE10250084A1 (de) * 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
WO2004054542A2 (en) 2002-12-13 2004-07-01 Durect Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
EP1782834A3 (en) * 2003-03-13 2007-08-01 Controlled Chemicals, Inc. Oxycodone conjugates with lower abuse potential and extended duration of action
US8906413B2 (en) * 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
EP2112920B1 (en) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
NZ545202A (en) * 2003-08-06 2010-03-26 Gruenenthal Chemie Abuse-proofed dosage form comprising opiods and a high molecular weight polyethylene oxide
EP1677768A4 (en) * 2003-10-03 2011-06-29 Elite Lab Inc PROLONGED RELEASE OPIOID FORMULATIONS AND METHOD OF USING THE FORMULATIONS
US20050163718A1 (en) * 2004-01-23 2005-07-28 Shugart Jack I. Injectable euthanasia compositions that include a taste aversive agent
GB0501638D0 (en) * 2005-01-28 2005-03-02 Euro Celtique Sa Particulates
DE102004019916A1 (de) * 2004-04-21 2005-11-17 Grünenthal GmbH Gegen Missbrauch gesichertes wirkstoffhaltiges Pflaster
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
ITMI20041317A1 (it) * 2004-06-30 2004-09-30 Ibsa Inst Biochimique Sa Formulazioni farmaceutiche per la somministrazione sicura di farmaci utilizzati nel trattamento della tossicodipendenza e procedimento per il loro ottenimento
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
FR2878161B1 (fr) * 2004-11-23 2008-10-31 Flamel Technologies Sa Forme medicamenteuse orale, solide et concue pour eviter le mesusage
US20070259045A1 (en) * 2005-01-28 2007-11-08 Euro-Celtique S.A. Alcohol Resistant Dosage Forms
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
FR2889810A1 (fr) * 2005-05-24 2007-02-23 Flamel Technologies Sa Forme medicamenteuse orale, microparticulaire, anti-mesurage
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
FR2892937B1 (fr) * 2005-11-10 2013-04-05 Flamel Tech Sa Forme pharmaceutique orale microparticulaire anti-mesusage
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
US9561188B2 (en) 2006-04-03 2017-02-07 Intellipharmaceutics Corporation Controlled release delivery device comprising an organosol coat
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
FR2901478B1 (fr) * 2006-05-24 2015-06-05 Flamel Tech Sa Forme pharmaceutique orale multimicroparticulaire a liberation prolongee
US9023400B2 (en) 2006-05-24 2015-05-05 Flamel Technologies Prolonged-release multimicroparticulate oral pharmaceutical form
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US8093261B2 (en) 2006-10-24 2012-01-10 The Johns Hopkins University Rapid release mini-tablets provide analgesia in laboratory animals
WO2009088414A2 (en) 2007-12-06 2009-07-16 Durect Corporation Oral pharmaceutical dosage forms
MX2010006694A (es) 2007-12-17 2010-09-07 Labopharm Inc Formulacion de liberacion controlada, preventiva de mal uso.
TWI454288B (zh) 2008-01-25 2014-10-01 Gruenenthal Chemie 藥物劑型
JP2011511782A (ja) 2008-02-12 2011-04-14 アボット・ラボラトリーズ 長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途
PT2273983T (pt) 2008-05-09 2016-10-28 Gruenenthal Gmbh Processo para a preparação de uma formulação em pó intermediária e uma forma de dosagem sólida final sob utilização de uma etapa de congelamento por atomização
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
WO2010069050A1 (en) * 2008-12-16 2010-06-24 Labopharm Inc. Misuse preventative, controlled release formulation
SG174286A1 (en) 2009-03-10 2011-10-28 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
RU2547555C2 (ru) 2009-07-22 2015-04-10 Грюненталь Гмбх Экструдированная из горячего расплава фармацевтическая лекарственная форма
KR101747156B1 (ko) 2009-07-22 2017-06-27 그뤼넨탈 게엠베하 산화-안정화된 탬퍼-내성 용량형
EP2611425B1 (en) 2010-09-02 2014-07-02 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
EP2611426B1 (en) 2010-09-02 2014-06-25 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
CA2827273A1 (en) * 2011-02-17 2012-08-23 QRxPharma Ltd. Technology for preventing abuse of solid dosage forms
US20130028972A1 (en) 2011-07-29 2013-01-31 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
DK2736495T3 (da) 2011-07-29 2017-11-13 Gruenenthal Gmbh Misbrugsbestandig tablet som tilvejebringer øjeblikkelig frigivelse af lægemiddel
EP2755640B1 (en) * 2011-09-16 2017-07-26 Purdue Pharma LP Tamper resistant pharmaceutical formulations
FR2983409B1 (fr) 2011-12-06 2013-12-27 Ethypharm Sa Comprime susceptible de lutter contre le detournement par voie injectable
GB201202433D0 (en) * 2012-02-13 2012-03-28 Diurnal Ltd Controlled drug release
CA2864949A1 (en) 2012-02-28 2013-09-06 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
EA028224B1 (ru) * 2012-03-02 2017-10-31 Роудс Фармасьютикалз Л.П. Лекарственные формы немедленного высвобождения с защитой от несанкционированного применения
KR101701013B1 (ko) * 2012-03-02 2017-01-31 로도스 파머시티컬스 엘.피. 부정조작 방지 즉각 방출 제형
EA201401139A1 (ru) 2012-04-18 2015-03-31 Грюненталь Гмбх Устойчивая к разрушению и к сбросу дозы фармацевтическая лекарственная форма
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
AU2013285988A1 (en) * 2012-07-06 2015-02-12 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
SG11201506064UA (en) * 2013-02-05 2015-08-28 Purdue Pharma Lp Tamper resistant pharmaceutical formulations
TW201521769A (zh) 2013-03-15 2015-06-16 Durect Corp 具有流變改質劑以減少溶解變異性之組成物
US10751287B2 (en) * 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US10420729B2 (en) 2013-03-15 2019-09-24 R.P. Scherer Technologies, Llc Abuse resistant capsule
MX371432B (es) 2013-05-29 2020-01-30 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido que contiene una o mas particulas.
JP6466417B2 (ja) 2013-05-29 2019-02-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
KR20160031526A (ko) 2013-07-12 2016-03-22 그뤼넨탈 게엠베하 에틸렌-비닐 아세테이트 중합체를 함유하는 템퍼 내성 투여형
WO2015011189A1 (en) 2013-07-23 2015-01-29 Euro-Celtique S.A. A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
CN105934241B (zh) 2013-11-26 2020-06-05 格吕伦塔尔有限公司 通过低温研磨制备粉末状药物组合物
CN105636581A (zh) * 2013-12-03 2016-06-01 豪夫迈·罗氏有限公司 药物组合物
EP3142646A1 (en) 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
MX2016015417A (es) 2014-05-26 2017-02-22 Gruenenthal Gmbh Multiparticulas protegidas contra vertido de dosis etanolico.
EP3285745A1 (en) 2015-04-24 2018-02-28 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
EP3473246A1 (en) 2017-10-19 2019-04-24 Capsugel Belgium NV Immediate release abuse deterrent formulations
AU2020234961A1 (en) * 2019-03-11 2021-09-30 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
KR20230114813A (ko) 2022-01-25 2023-08-02 정광선 암염 좌욕기

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869097A (en) * 1992-11-02 1999-02-09 Alza Corporation Method of therapy comprising an osmotic caplet

Also Published As

Publication number Publication date
MXPA04001206A (es) 2004-07-08
DE20220917U1 (de) 2004-08-19
JP2005500364A (ja) 2005-01-06
KR20040025741A (ko) 2004-03-25
CA2455420A1 (en) 2003-02-20
IL160217A0 (en) 2004-07-25
BR0212020A (pt) 2005-08-16
WO2003013476A1 (en) 2003-02-20
EP1414413A1 (en) 2004-05-06
WO2003013476B1 (en) 2003-07-03

Similar Documents

Publication Publication Date Title
HUP0401344A2 (hu) Gyógyszerkészítmények opioidokkal való visszaélés megakadályozására, és eljárás előállításukra
HUP0401195A2 (hu) Averziót okozó szert tartalmazó készítmények opioidokkal való visszaélés megakadályozására
JP2005515966A5 (hu)
WO2002067903A3 (en) Compositions and methods of manufacture for oral dissolvable dosage forms
AU1079701A (en) Oral transmucosal drug dosage using solid solution
FI964593A (fi) Oraalisia nestemäisiä alendronaattikokoonpanoja
HUP0302114A2 (hu) Eritropoietin-fehérjét tartalmazó folyékony gyógyászati készítmény, eljárás előállítására és alkalmazása
HUP0402217A2 (hu) Platinaszármazékot tartalmazó gyógyászati készítmények
KR20080108068A (ko) 아고멜라틴의 구강점막 또는 설하 투여를 위한 구강내분산성 약제 조성물
CA2503810A1 (en) Therapeutic agent for fibromyalgia
BG105173A (en) Novel salt form of pantoprazole
HUP0105173A2 (hu) Adagolási módszer és készítmény sürgősségi fogamzásgátlásra
JP2005516904A5 (hu)
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
MXPA05013270A (es) Forma de administracion transmucosal con irritacion mucosal reducida. reducida.
JP2001031562A (ja) 内服液剤
HUP0303178A2 (hu) Eljárások és készítmények gyógyászatilag aktív anyagok ízének csökkentésére
EP1694295B1 (en) Pharmaceutical oral dosage form comprising a non-steroidal anti-inflammatory drug, and having good palatability
CN100548281C (zh) 用于递送催眠药穿过口腔粘膜的组合物及其用法
JP2005511653A6 (ja) 神経麻痺及び神経機能障害に対する治療の為の経皮薬物
KR100344198B1 (ko) 실데나필 시트레이트의 속효제형
JPS6296418A (ja) 薬用チユ−インガム
JPH11302189A (ja) 感冒用組成物
JPH0977675A (ja) 生薬配合発泡錠
CA2515259A1 (en) Use of acetylsalicylic acid for the treatment of hemorrhoidal disease

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees